^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    TP53 I255N

    i
    Other names: TP53, Tumor Protein P53, Cellular Tumor Antigen P53, Phosphoprotein P53, Tumor Protein P53, Antigen NY-CO-13, Transformation-Related Protein 53, Mutant Tumor Protein 53, P53 Tumor Suppressor, Tumor Suppressor P53, Tumor Protein 53, BMFS5, TRP53, BCC7, LFS1
    Entrez ID:
    7157
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Associations

    News

    Trials
    over1year
    Impact of subclonal IDH mutation status on overall survival in high-grade gliomas (AANP 2023)
    No significant association was seen with CDKN2A homozygous deletion and MGMT methylation status. Conclusions Our findings highlight the potential clinical utility of quantified IDH1 R132H expression by IHC and/or VAF by NGS.
    Clinical • Tumor mutational burden
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MGMT (6-O-methylguanine-DNA methyltransferase) • MSH2 (MutS Homolog 2) • ATRX (ATRX Chromatin Remodeler)
    |
    TP53 mutation • TMB-H • IDH1 mutation • CDKN2A deletion • ATRX mutation • IDH1 R132H • MSH2 mutation • IDH wild-type • IDH1 R132 • TP53 I255N